Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.
You may also be interested in...
Deals Of The Week: Merck/Simcere, Pfizer/Hisun, MedImmune/WuXi
The growing importance of emerging markets will be a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York
Pulmatrix Inc.
Originally intent on developing a contagion-prevention product for biodefense, Pulmatrix Inc. now has much larger ambitions. The company believes its new technologies for formulating drugs as dry powders and delivering them via inhalers will make its lead respiratory drug candidate more convenient and potent. Pulmatrix also sees the methods as a discovery engine likely to give rise to partnerships and branded generics.
Pulmatrix Gets $30M And An NIH Grant To Develop A Broad-Spectrum Anti-Infective
Biotech's technology uses two mechanisms of action to prevent infection and keep pathogens from entering the lungs.